Table S3.

Time to response by treatment for prior MPH or stimulant-naïve subgroups (LOCF, full-analysis set)

Definition of response	Time to response	RCT						RWS
		Placebo (n=111)		GXR (n=114)		ATX (n=112)		GXR (n=503)
		Prior MPH	Stimulant-naïve	Prior MPH	Stimulant-naïve	Prior MPH	Stimulant-naïve	Prior MPH	Stimulant-naïve
≥50% reduction from baseline in ADHD-RS-IV	Number of participants	23	25	31	41	24	36	169	174
total score	Median (95% CI), days	57 (35–IC)	84 (56–IC)	34 (22–48)	34 (28–67)	49 (37–IC)	56 (35–70)	36 (35–42)	29 (27–35)
				P=0.013	P=0.001	P=0.629	P=0.061
≥30% reduction from baseline in ADHD-RS-IV	Number of participants	28	36	37	50	38	49	198	191
total score	Median (95% CI), days	28 (26–43)	36 (28–56)	21 (14–27)	25 (20–33)	28 (21–33)	28 (21–35)	23 (21–27)	20 (15–21)
				P=0.024	P=0.006	P=0.216	P=0.042

Note: P-values from a log-rank test stratified by age-group and country.

Abbreviations: ADHD-RS-IV, Attention-Deficit/Hyperactivity Disorder Rating Scale version IV; ATX, atomoxetine; CI, confidence interval; GXR, guanfacine extended release; IC, incalculable; LOCF, last observation carried forward; MPH, methylphenidate; RCT, randomized controlled trial; RWS, randomized-withdrawal study.